International Flavors & Fragrances Inc. (IFF) is scheduled to report first-quarter 2025 results on May 6, after the closing bell.The Zacks Consensus Estimate for IFF’s sales is pegged at $2.83 billion, indicating a 2.2% dip from the year-ago reported figure.The consensus estimate for earnings is pegged at $1.12 per share. The consensus estimate for IFF’s earnings has moved up 2.7% in the past 60 days. The estimate indicates a year-over-year dip of 0.9%. (Stay up-to-date with all quarterly releases: See Zack ...

Wall Street analysts expect International Flavors (IFF) to post quarterly earnings of $1.12 per share in its upcoming report, which indicates a year-over-year decline of 0.9%. Revenues are expected to be $2.83 billion, down 2.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.6% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior to a co ...

International Flavors & Fragrances (IFF) FY 2025 Annual General Meeting May 01, 2025 10:00 AM ET Speaker0 Welcome to the International Flavors and Fragrance Inc twenty twenty five Annual Shareholder Meeting. I'll now hand over to Jennifer Johnson. Speaker1 Good morning, ladies and gentlemen. My name is Jennifer Johnson, and I am the general counsel and corporate secretary of International Flavors and Fragrances. I would like to welcome all of you to the twenty twenty five IFF Annual Meeting of Shareholders. ...

Wall Street expects a year-over-year decline in earnings on lower revenues when International Flavors (IFF) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 6. ...

International Flavors & Fragrances Inc. (IFF) announced plans to consolidate the majority of its business operations in Mexico at a new site within the Tecnoparque business complex in Mexico City. This move will boost the company’s ability to meet customer demands, facilitate product market entry and enhance sustainability.IFF’s Move to Tecnoparque to Boost Regional GrowthInternational Flavors' new facility in Tecnoparque will feature labs for product creation, design, testing, R&D and business services, as ...

International Flavors (IFF) shares ended the last trading session 9.2% higher at $72.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.3% loss over the past four weeks.International Flavors’ shares got a boost yesterday after U.S President Trump announced a 90-day pause on certain tariffs for most countries (except China). IFF’s shares also gained since the company announced that it partnered with Florida Poly ...

International Flavors & Fragrances Inc. (IFF) shares have lost 24.4% in the past six months compared with the industry’s 8.3% decline. This mainly reflects the impacts of lower volumes in the Food Ingredients business and higher manufacturing expenses. Supply-chain challenges and the effects of the Pharma segment divestiture have also impacted IFF’s results.  Image Source: Zacks Investment Research Low Volume, High Costs Act as WoesInternational Flavors continues to incur high raw material costs and additio ...

A month has gone by since the last earnings report for International Flavors (IFF) . Shares have lost about 1.8% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is International Flavors due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Sin ...

Financial Performance - In 2024, total sales were $11.484 billion, remaining flat compared to $11.479 billion in 2023, but increased by 3% on a currency neutral basis [240]. - Gross profit in 2024 increased by $443 million, or 12%, to $4.124 billion, representing 35.9% of sales, compared to 32.1% in 2023 [242]. - Total net sales for 2024 were $11.484 billion, a slight increase from $11.479 billion in 2023, with a comparable portfolio excluding divestitures showing a growth of approximately $244 million [246]. - Segment Adjusted Operating EBITDA increased to $2.205 billion in 2024, up from $1.980 billion in 2023, with a total margin of 19.2% compared to 17.2% in the previous year [267]. Sales by Segment - The Nourish segment experienced a 3% decline in sales, while the Health & Biosciences segment saw a 6% increase in reported sales [245]. - Nourish segment sales decreased by $189 million, or 3%, to $5.871 billion in 2024, while currency neutral sales increased by 4% driven by volume increases across all business units [247]. - Health & Biosciences segment sales increased by $131 million, or 6%, to $2.212 billion in 2024, with an 8% increase on a currency neutral basis due to volume and price increases [248]. - Scent segment sales rose by $47 million, or 2%, to $2.440 billion in 2024, with a 7% increase on a currency neutral basis driven by price and volume increases [249]. - Pharma Solutions segment sales increased by $16 million, or 2%, to $961 million in 2024, maintaining a 2% increase on a currency neutral basis [251]. Expenses - Research and development (R&D) expenses increased by 6% to $671 million in 2024, representing 5.8% of sales [244]. - Selling and Administrative (S&A) expenses rose by $208 million to $1.995 billion, representing 17.4% of sales in 2024, up from 15.6% in 2023 [254]. - Cost of sales decreased by $438 million to $7.360 billion, representing 64.1% of sales in 2024, down from 67.9% in 2023 [252]. Impairment Charges - The company recorded an impairment charge of $64 million for the Pharma Solutions segment in 2024, significantly lower than the $2.623 billion impairment in the Nourish segment in 2023 [230][231]. - The Company recorded a non-cash goodwill impairment charge of $64 million for the Pharma Solutions disposal group during the quarter ended June 30, 2024 [316]. - A goodwill impairment charge of $2.623 billion was recorded for the Nourish reporting unit for the year ended December 31, 2023 [319]. - The Company anticipates a material impairment charge in the range of $1.0 billion to $1.5 billion in the first quarter of fiscal 2025 due to the restructuring of the Nourish segment into two operating segments: Taste and Food Ingredients [321]. Taxation - The effective tax rate for 2024 was 11.2%, compared to a negative rate of 1.8% in 2023 [244]. - The effective tax rate increased to 11.2% in 2024 from (1.8)% in 2023, primarily due to an increase in pre-tax income and changes in the mix of earnings [262]. Cash Flows - Cash flows from operating activities in 2024 were $1.070 billion, or 9.3% of sales, down from $1.439 billion, or 12.5% of sales in 2023 [276]. - Cash flows from investing activities decreased to $326 million in 2024 from $574 million in 2023, primarily due to lower net proceeds from business divestitures [277]. - Cash flows used in financing activities were $1.606 billion in 2024, a decrease from $1.851 billion in 2023, mainly due to lower dividends paid [279]. - Dividends paid totaled $514 million in 2024, down from $826 million in 2023, with cash dividend declared per share at $1.60 compared to $3.24 in 2023 [280]. Debt and Capital Management - As of December 31, 2024, the net debt to credit adjusted EBITDA ratio was 3.84 to 1.0, below the covenant limit [287]. - Total debt as of December 31, 2024, was approximately $9.005 billion, with net debt at $8.534 billion [290]. - The company had $8.478 billion in senior unsecured notes outstanding, with effective interest rates ranging from 1.22% to 5.12% [291]. - The company had no outstanding borrowings under its $2 billion Revolving Credit Facility as of December 31, 2024, with available capacity of $922 million [286]. - The company anticipates capital spending in 2025 to be approximately 6% of sales [278]. - The company plans to prioritize capital investment in its businesses to support strategic long-term plans while maintaining its investment grade rating [281]. Foreign Currency and Risk Management - The company actively monitors foreign currency exposures and employs various techniques, including hedging activities, to mitigate the impact of exchange rate fluctuations [335]. - As of December 31, 2024, the estimated fair value of foreign currency forward contracts would change by approximately $475 million with a hypothetical 10% change in applicable exchange rates [337]. - The aggregate fair value of cross currency swaps was $90 million as of December 31, 2024, with an estimated change of approximately $143 million based on a hypothetical 10% change in the value of the U.S. dollar against the Euro [338]. - The fair value of EUR fixed rate debt was $813 million as of December 31, 2024, with an estimated change of approximately $90 million based on a hypothetical 10% change in foreign exchange rates [339]. - The fair value of USD fixed rate debt was $6.338 billion as of December 31, 2024, with an estimated change of approximately $634 million based on a hypothetical 10% change in interest rates [339]. - The total amount of outstanding debt subject to interest rate fluctuations was $413 million as of December 31, 2024, with an estimated annual interest expense change of approximately $4 million based on a hypothetical 1% change in interest rates [340]. - The company has established a centralized reporting system to evaluate the effects of changes in interest rates and currency exchange rates [336]. - The company enters into foreign currency forward contracts to manage exchange rate risk related to foreign currency denominated monetary assets and liabilities [337]. - The company does not generally use commodity financial instruments to hedge commodity prices, except for soy and natural gas [341]. - The company utilizes statistical analyses of cash flows and sensitivity analysis as part of its risk management procedures [336].

International Flavors & Fragrances Inc. (NYSE:IFF) Q4 2024 Earnings Call Transcript February 19, 2025 9:00 AM ET Company Participants Michael Bender - Director, Investor Relations Erik Fyrwald - Chief Executive Officer Michael DeVeau - EVP, Chief Financial Officer Conference Call Participants Kristen Owen - Oppenheimer Josh Spector - UBS Nicola Tang - BNP Paribas Emily Fusco - Deutsche Bank Eric Zhang - Citi Lisa Neve - Morgan Stanley Steve Byrne - Bank of America John Roberts - Mizuho Mike Sison - Wells Fa ...